Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen

Documenti analoghi

• Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis associated colon cancer
  di: Beatty, Pamela L., et al.
  Pubblicazione: (2010)
• Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer
  di: Cascio, Sandra, et al.
  Pubblicazione: (2017)
• Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses
  di: Ryan, Sean O., et al.
  Pubblicazione: (2010)
• Inflammation Driven by Overexpression of the Hypoglycosylated Abnormal MUC1 Links Inflammatory Bowel Disease (IBD) and Pancreatitis
  di: Kadayakkara, Deepak K., et al.
  Pubblicazione: (2010)
• Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments
  di: Reichenbach, Dawn K., et al.
  Pubblicazione: (2013)